MNOV
MEDICINOVA INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Sep 17 Roth Capital initiates
- Sep 18 Trading halt: Halt Resumed: MNOV, trading resumed after LUDP (Volatility…
- Sep 18 Trading halt: Trading Halt: MNOV, LUDP (Volatility Trading Pause)
- Sep 24 MediciNova announced completion of the last patient's final visit in…
- Sep 24 FDA: MediciNova Announces Completion of Last Patient, Last Visi…
- Sep 25 ▼ 1 insider sell $1.7M at $2.70
- Sep 28 FDA: MediciNova Announces Topline Results from MN-001-NATG-202…
- Oct 2 Trial readout: T-90d Trial Readout: MN-001 (Phase 2)
- Oct 5 Trial readout: T-90d Trial Readout: MN-001 (Phase 2)
- Oct 12 Trial readout: T-90d Trial Readout: MN-001 (Phase 2)
- Oct 26 Trial readout: T-90d Trial Readout: MN-001 (Phase 2)
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider sold $1.7M.
- InstitutionsMIXED
Q3 2026: 3 added (0 new), 3 trimmed or exited.
- AnalystsBULLISH
9 of 10 rate it Buy or better.
- Short sellersSTEADY
Short interest −2.4% to 285.2K shares. 5.4 days to cover, ≈0.6% of shares.
- TrendDOWNTREND
25% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | DOUBLED | $5.4M |
| JANE STREET GROUP, LLC | DOUBLED | $212.7K |
| UBS Group AG | NEAR_EXIT | $60.8K |
| BARCLAYS PLC | TRIM | $39.8K |
| BARCLAYS PLC | TRIM | $56.5K |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | TRIM | $35.3K |
| JANE STREET GROUP, LLC | NEAR_EXIT | $20.9K |
| BANK OF AMERICA CORP /DE/ | TRIM | $17.4K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
10 analysts| Date | Firm | Rating |
|---|---|---|
| Sep 17, 2026 | Roth Capital INITIATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
3D Investment Partners Pte. Ltd. Sep 25, 2026 | SELL | $1.7M |
Lemerond Nicole Director Jun 23, 2026 | AWARD | 44,500 sh |
BEAVER CAROLYN Director Jun 23, 2026 | AWARD | 44,500 sh |
Nagao Hideki Director Jun 23, 2026 | AWARD | 44,500 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | -$0.08 | -$0.08–-$0.08 | No data | $0.00 |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026| Sep 18, 2026 | Volatility Pause | Resumed |
SecBot reports
4 filings · 2 press releases · 1 bullish · 1 bearish · 2 neutral- BEARISH 8-KNov 16, 2026
CFO Jason Kruger resigned effective November 10, 2026, with no stated disagreement. CEO Yuichi Iwaki, age 76, was appointed interim CFO without additional compensation.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13GOct 30, 2026
Vanguard Capital Management LLC disclosed a 7.20% passive stake in MediciNova Inc via Schedule…
This is a routine passive disclosure by an index fund manager. No change in control intent is signaled. Monitor for any future amendments that increase the stake above 10% or a conversion to…
- MIXED PRESS RELEASESep 28, 2026
MediciNova reported Phase 2 topline results for MN-001 (tipelukast) in hypertriglyceridemia and…
The mixed Phase 2 data for MN-001 in NAFLD/hypertriglyceridemia provides a proof-of-concept signal but lacks the statistical significance needed for a near-term catalyst. Watch for details on the…
- MIXED PRESS RELEASESep 24, 2026
MediciNova announced completion of the last patient's final visit in the double-blind portion of…
The binary catalyst is topline data by end of 2026. ALS is a large unmet-need market with no cure; positive CAFS data would likely drive significant upside for this single-asset-stage biotech…
All MNOV filing & press-release reports (6)
- 8-K reportNov 16, 2026
- SC 13G reportOct 30, 2026
- PRESS-RELEASE reportSep 28, 2026
- PRESS-RELEASE reportSep 24, 2026
- 8-K reportSep 2, 2026
- 8-K reportAug 19, 2026